AstraZeneca: Farxiga granted breakthrough therapy status
(CercleFinance.com) - AstraZeneca announced on Friday that the FDA has granted "breakthrough therapy" status to its diabetes drug Farxiga in the treatment of chronic kidney failure.
The approval from the US health authority, which concerns both diabetic and non-diabetic patients, will offer 37 million Americans suffering from this pathology a new treatment option.
Farxiga reduces the renal reabsorption of glucose by increasing its excretion in urine.
For several years AstraZeneca has been focusing on the cardiovascular, renal and metabolic fields, which represent its priority therapeutic areas.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The approval from the US health authority, which concerns both diabetic and non-diabetic patients, will offer 37 million Americans suffering from this pathology a new treatment option.
Farxiga reduces the renal reabsorption of glucose by increasing its excretion in urine.
For several years AstraZeneca has been focusing on the cardiovascular, renal and metabolic fields, which represent its priority therapeutic areas.
Copyright (c) 2020 CercleFinance.com. All rights reserved.